Does novel small molecule glucagon-like peptide-1 receptor agonist stimulate insulin secretion in rodents and from human islets?
These studies characterize the insulinotropic effects of an early-stage, small molecule GLP-1 receptor agonist and provide compelling evidence to support pharmaceutical optimization.
A dedicated program for young breast cancer patients is associated with a higher frequency of FP referrals without delaying systemic therapy.